Laboratorios Farmaceuticos ROVI SA
MAD:ROVI

Watchlist Manager
Laboratorios Farmaceuticos ROVI SA Logo
Laboratorios Farmaceuticos ROVI SA
MAD:ROVI
Watchlist
Price: 63 EUR 1.86% Market Closed
Market Cap: 3.2B EUR
Have any thoughts about
Laboratorios Farmaceuticos ROVI SA?
Write Note

Laboratorios Farmaceuticos ROVI SA
Operating Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Laboratorios Farmaceuticos ROVI SA
Operating Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
Laboratorios Farmaceuticos ROVI SA
MAD:ROVI
Operating Income
€281.7m
CAGR 3-Years
12%
CAGR 5-Years
40%
CAGR 10-Years
26%
Almirall SA
MAD:ALM
Operating Income
€58.7m
CAGR 3-Years
-30%
CAGR 5-Years
-18%
CAGR 10-Years
N/A
F
Faes Farma SA
MAD:FAE
Operating Income
€145.2m
CAGR 3-Years
19%
CAGR 5-Years
6%
CAGR 10-Years
18%
Laboratorio Reig Jofre SA
MAD:RJF
Operating Income
€17m
CAGR 3-Years
21%
CAGR 5-Years
6%
CAGR 10-Years
29%
No Stocks Found

Laboratorios Farmaceuticos ROVI SA
Glance View

Market Cap
3.3B EUR
Industry
Pharmaceuticals

Laboratorios Farmaceúticos Rovi SA engages in the research, development, manufacture, and marketing of small molecule and specialty biologic drugs. The company is headquartered in Madrid, Madrid and currently employs 1,751 full-time employees. The company went IPO on 2007-10-26. The Company’s main activities include the development and commercialization, nationwide and abroad, of medicines and drugs. Its products are structured into three fields: Diagnostic, which offers contrast mediums for use in magnetic resonance, ultrasound and X-ray diagnostics; Prescription, which distributes medicines under such brands as Hibor, Osseor, Hepadren, Pneumovax-23, Glufan, Corlentor, Exxiv, Calcio y Vitamina D3 Rovi and Absorcol, among others; and Over The Counter (OTC), which comprises the Perspirex, Enerzona, Dentimelo and ColdPack brands. The firm owns such fully consolidated subsidiaries as Gineladius SL, Frosst Iberica SA, Rovi Contract Manufacturing SL and Bertex Pharma GmbH, among others.

ROVI Intrinsic Value
83.93 EUR
Undervaluation 25%
Intrinsic Value
Price

See Also

What is Laboratorios Farmaceuticos ROVI SA's Operating Income?
Operating Income
281.7m EUR

Based on the financial report for Sep 30, 2024, Laboratorios Farmaceuticos ROVI SA's Operating Income amounts to 281.7m EUR.

What is Laboratorios Farmaceuticos ROVI SA's Operating Income growth rate?
Operating Income CAGR 10Y
26%

Over the last year, the Operating Income growth was -23%. The average annual Operating Income growth rates for Laboratorios Farmaceuticos ROVI SA have been 12% over the past three years , 40% over the past five years , and 26% over the past ten years .

Back to Top